title: Baseline levels and decrease in serum soluble intercellular adhesion molecule-1 during chemotherapy predict objective response and survival in patients who have advanced non-small-cell lung cancer.
abstract: BACKGROUND
  This study assesses the predictive and prognostic roles of serum soluble intercellular adhesion molecule-1 (sICAM-1) and vascular endothelial growth factor (VEGF) during chemotherapy in patients with advanced non-small-cell lung cancer (NSCLC).
  
  
  METHODS
  Changes in serum levels of sICAM-1 and VEGF during first-line conventional chemotherapy were studied prospectively using an enzyme-linked immunosorbent assay at baseline and after every two courses of therapy in 124 patients who have advanced NSCLC. Data were correlated with radiologic objective response and survival.
  
  
  RESULTS
  The prognostic values of serum sICAM-1and VEGF were explored in 115 advanced NSCLC patients and 61 patients were evaluated for radiologic and serologic responses after two chemotherapy courses. Of the 115 patients, 79 patients had baseline serum sICAM-1 levels greater than 232.84 ng/mL, which is the cut-off value for distinguishing malignant tumors from benign. Statistically significant correlations were observed between baseline sICAM-1 levels and odds ratios and between a sICAM-1 response and odds ratios (8.05 and 5.40, respectively). However, there was no correlation between baseline VEGF levels and odds ratios (P = .543). The median progression-free survival from response assessment was 4 months. In a multivariate analysis, performance status (hazard ratio [HR], 1.47; 95% confidence interval [CI] (95% CI), 1.03-2.10), disease stage (HR, 1.43; 95% CI, 1.07-1.90), baseline sICAM-1 (HR, 1.12; 95% CI, 1.01-1.21), and sICAM-1 response (HR, 0.58; 95%CI, 0.39-0.88), were confirmed as independent prognostic factors for survival.
  
  
  CONCLUSIONS
  Baseline sICAM-1 and sICAM-1 responses appeared to be reliable surrogate markers of chemotherapy efficacy and were prognostic factors in patients with advanced NSCLC.
authors.affiliation: Department of Respiratory Medicine, Jinling Hospital, Nanjing University School of Medicine, China.
authors.forename: Qian
authors.initials: Q
authors.lastname: Qian
authors.forename: Ping
authors.initials: P
authors.lastname: Zhan
authors.forename: Like
authors.initials: L
authors.lastname: Yu
authors.forename: Yi
authors.initials: Y
authors.lastname: Shi
authors.forename: Jinfei
authors.initials: J
authors.lastname: Cheng
authors.forename: Shuzhen
authors.initials: S
authors.lastname: Wei
authors.forename: Qian
authors.initials: Q
authors.lastname: Wang
authors.forename: Yong
authors.initials: Y
authors.lastname: Song
mesh_terms: D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use; D014408:Biomarkers, Tumor / Q000097:blood; D002289:Carcinoma, Non-Small-Cell Lung / Q000097:blood* / Q000188:drug therapy* / Q000473:pathology; D018572:Disease-Free Survival; D005260:Female; D006801:Humans; D018799:Intercellular Adhesion Molecule-1 / Q000097:blood*; D008175:Lung Neoplasms / Q000097:blood* / Q000188:drug therapy* / Q000473:pathology; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D011237:Predictive Value of Tests; D011379:Prognosis; D011446:Prospective Studies; D015203:Reproducibility of Results; D015996:Survival Rate; D016896:Treatment Outcome; D042461:Vascular Endothelial Growth Factor A / Q000097:blood*
chemical_list: D000970:Antineoplastic Agents; D014408:Biomarkers, Tumor; D042461:Vascular Endothelial Growth Factor A; D018799:Intercellular Adhesion Molecule-1